Search Results
Oct 08, 2025, 19:40 ET PROCURE PROTON THERAPY CENTER URGES NEWS ORGANIZATIONS TO RAISE AWARENESS OF THE IMPORTANCE OF EARLY BREAST CANCER DETECTION AND TREATMENT OPTIONS
opened in March 2012 as the tri-state region's first proton therapy facility, treating a range of cancers including diseases of the prostate, breast, lung, brain, head and neck, and gastrointestinal system, as well as sarcomas and many pediatric cases. Using the most advanced radiation treatment available,
More news about: ProCure Proton Therapy Center
Oct 08, 2025, 17:44 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR
"announce[ing] topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease." The press release disclosed, in relevant part, that the trial had failed to meet its primary endpoint. On this news,
More news about: Pomerantz LLP
Oct 08, 2025, 16:30 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRA
in a Phase 3 IMPALA-2 pivotal clinical trial for the treatment of autoimmune pulmonary alveolar proteinosis ("aPAP"), a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Savara has consistently represented that, based on investments
More news about: Pomerantz LLP
Oct 08, 2025, 16:15 ET WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
Company. The Company intends to use the net proceeds from the offering for working capital, to support expected growing sales for CyPath® Lung, its noninvasive test for lung cancer, and general corporate purposes. The common stock described above is being offered by the Company pursuant
More news about: WallachBeth Capital LLC
Oct 08, 2025, 16:00 ET Visionary Holdings Inc. Announces 2025 Annual Meeting of Shareholders
Simon Lung Lung Tang
More news about: Visionary Holdings Inc.
Oct 08, 2025, 14:02 ET Synchrony Medical Launches LibAirty™ Airway Clearance System in the U.S., Offering a New Standard for At-Home Respiratory Care
LibAirty™ Airway Clearance System in the United States. The launch marks an important step forward for people living with chronic lung disease, providing access to advanced at-home therapy designed to improve daily breathing, reduce exacerbations and hospitalizations, and enhance quality
More news about: Synchrony Medical
Oct 08, 2025, 12:27 ET Rotary Air Preheaters Market Size to Reach USD 1.8 Billion by 2033, Growing at 5.2% CAGR from 2026-2033 - Market Research Intellect
Global Checkpoint Inhibitors For Treating Cancer Market Size By Application (Lung Cancer, Melanoma, Bladder Cancer, Hodgkin Lymphoma, Head and Neck Cancers), By Product (PD-1 Inhibitors (Programmed Cell Death Protein 1), PD-L1 Inhibitors
More news about: Market Research Intellect
Oct 08, 2025, 10:58 ET Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
candidate moving toward the clinic. GTB-5550 targets a protein called B7H3 that appears in many different types of solid tumors, including breast, lung, ovarian, head and neck, pancreatic, bladder, and prostate cancers. The company expects to
More news about: Equity Insider
Oct 08, 2025, 08:00 ET Biond Biologics Announces Initiation of a Phase 2 Study of BND-22 in Combination with anti-PD-1 therapy
pembrolizumab. The phase 2 included evaluations of BND-22 as monotherapy in cholangiocarcinoma and in combination with cetuximab in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). https://clinicaltrials.gov/ (Trial
More news about: Biond Biologics Ltd.
Oct 08, 2025, 07:30 ET Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the acceptance of two abstracts for presentation at the
More news about: Trevi Therapeutics, Inc.
Oct 08, 2025, 06:07 ET Breathe Easy This Winter: New Campaign Urges Vaccination to Protect Against Seasonal Flu and Other Respiratory Illnesses
About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Oct 07, 2025, 16:20 ET Joe DiMaggio Children's Hospital Achieves National Recognition with 6 Specialties Ranked by U.S. News & World Report
personalized care to support the mental well-being of young patients. Pediatric Nephrology, Pulmonology & Lung Surgery, and Urology Joe DiMaggio Children's Hospital is also nationally ranked in these additional specialties, reinforcing
More news about: Memorial Healthcare System
Oct 07, 2025, 16:17 ET SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the MOLBREEVI (a clinical trial for the treatment of a rare lung disease) Biologics License Application ("BLA") lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (2) accordingly,
More news about: THE ROSEN LAW FIRM, P. A.
Oct 07, 2025, 14:11 ET Circulogene Expands Solid Tumor Genomic Capabilities with Launch of OncoGenDx Tissue Assay
portfolio—including OncoGenLDx, the industry's only plasma-based test reporting PD-L1 expression, and LungLifeAI, a targeted solution for risk stratifying incidental lung nodules—the new assay reflects Circulogene's ongoing commitment to advancing precision oncology with fast, modular, and clinically actionable testing
More news about: Circulogene
Oct 07, 2025, 12:00 ET NEW RESEARCH FROM END WELL REVEALS TELEVISION SPARKS END-OF-LIFE CONVERSATIONS: VIEWERS SIGNIFICANTLY MORE LIKELY TO DISCUSS MORTALITY AFTER WATCHING AUTHENTIC STORYLINES
diagnosis and desire to die with dignity, and The Gentle Art of Swedish Death Cleaning's episode about Shana preparing for death after a stage 4 lung cancer diagnosis. Participants were randomly assigned to view either the end-of-life storylines or control clips from the same shows without mortality
More news about: End Well
Oct 07, 2025, 11:05 ET Seattle Children's Remains Among Top 10 Best Children's Hospitals in the Nation
Neonatology. Nephrology. Neurology & Neurosurgery. Pulmonology & Lung Surgery. Urology. Seattle Children's was named the No. 1 pediatric hospital
More news about: Seattle Children’s
Oct 07, 2025, 10:20 ET Multi Cancer Early Detection Testing Market to Reach US$ 7.52 Billion by 2033 as Galleri, CancerSEEK, and Next-Gen Liquid Biopsies Lead Global Adoption
through partnerships involving Johns Hopkins, captured 25% of the market (US$ 480 million). The test is expanding rapidly in colorectal, ovarian, and lung cancer detection. By Cancer Type Breast
More news about: DataM Intelligence 4 Market Research LLP
Oct 07, 2025, 09:00 ET Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
candidate moving toward the clinic. GTB-5550 targets a protein called B7H3 that appears in many different types of solid tumors, including breast, lung, ovarian, head and neck, pancreatic, bladder, and prostate cancers. The company expects to
More news about: USA News Group
Oct 07, 2025, 08:34 ET GeneVentiv Therapeutics Selected into NHLBI Catalyze Program to Fund IND-Enabling Toxicology Study for GENV-HEM
pioneering next-generation gene therapies for rare diseases, today announced that it has been selected into the Catalyze Program of the National Heart, Lung, and Blood Institute (NHLBI). Through this program, NIH will fund and provide preclinical services with leading national providers for the GLP toxicology
More news about: GeneVentiv Therapeutics
Oct 07, 2025, 08:30 ET Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Oct 07, 2025, 08:30 ET Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
Development Pathway and Combinations The program will initially target advanced breast cancer and non-small cell lung cancer (NSCLC), where PD-1/PD-L1 immunotherapies are widely used but resistance remains common. IND-enabling studies are expected to commence within
More news about: Kazia Therapeutics Limited
Oct 07, 2025, 08:00 ET Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
European Society for Medical Oncology Congress October 17-21[1] are unveiling pivotal survival data[2] and late-breaking lung cancer[3] results that demonstrate how diverse mechanisms are succeeding where traditional approaches stalled, while regulatory agencies
More news about: Equity Insider
Oct 07, 2025, 08:00 ET Texas Children's Hospital Named No. 1 Pediatric Hospital in Texas for 17th Consecutive Year; All Specialties Top Ranked Nationally Again
Pulmonology and Lung Surgery No. 1:
More news about: Texas Children's Hospital
Oct 07, 2025, 08:00 ET Apnimed Announces Acceptance of Two Late-breaking Presentations and a Core Interactive Session at the CHEST Annual Meeting Highlighting New Positive AD109 Phase 3 Data and the Current Unmet Need in Obstructive Sleep Apnea
Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep ApneaSession ID: Late-Breaking Scientific Abstracts Posters: Airways, Obstructive Lung Diseases, Bronch & CFSession Date: Tuesday, October 21, 2025Presentation Time: 1:45 - 2:30 PM CDTPoster
More news about: Apnimed, Inc.
Oct 07, 2025, 07:59 ET Children's Hospital Colorado Named One of the Nation's Top Children's Hospitals
Cardiology and heart surgery, No. 2 Diabetes and endocrinology, No. 3 Pulmonology and lung surgery, No. 4 Cancer, No. 4 Gastroenterology and GI surgery, No. 7
More news about: Children's Hospital Colorado